Focused On-demand Library for Tumor suppressor candidate 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q13454

UPID:

TUSC3_HUMAN

Alternative names:

Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit TUSC3; Magnesium uptake/transporter TUSC3; Protein N33

Alternative UPACC:

Q13454; A8MSM0; D3DSP2; Q14911; Q14912; Q96FW0

Background:

Tumor suppressor candidate 3 (TUSC3) plays a crucial role in protein glycosylation, acting as an accessory component of the N-oligosaccharyl transferase (OST) complex. This complex is pivotal for transferring high mannose oligosaccharides to nascent polypeptide chains, a process essential for proper protein folding and stability. TUSC3 is also known for its function in magnesium transport, highlighting its multifaceted role in cellular physiology.

Therapeutic significance:

The association of TUSC3 with Intellectual developmental disorder, autosomal recessive 7, underscores its potential as a therapeutic target. Understanding the role of TUSC3 could open doors to potential therapeutic strategies, offering hope for interventions in genetic disorders linked to protein glycosylation defects.